Capricor Therapeutics Inc (OTCMKTS:CAPR) shares rose 11.3% on Tuesday . The company traded as high as $3.19 and last traded at $2.75. Approximately 5,964,700 shares were traded during trading, an increase of 471% from the average daily volume of 1,044,131 shares. The stock had previously closed at $2.47.

CAPR has been the topic of a number of analyst reports. HC Wainwright lifted their target price on shares of Capricor Therapeutics from $2.15 to $6.50 and gave the company a “buy” rating in a research note on Friday, September 15th. Rodman & Renshaw restated a “buy” rating and set a $2.15 target price on shares of Capricor Therapeutics in a research note on Saturday, July 22nd. ValuEngine upgraded shares of Capricor Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, October 2nd. Finally, Zacks Investment Research upgraded shares of Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research note on Wednesday, August 16th.

Capricor Therapeutics (OTCMKTS:CAPR) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.07. The company had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $1.00 million. Capricor Therapeutics’s quarterly revenue was down 58.7% on a year-over-year basis. During the same period last year, the firm earned ($0.29) earnings per share.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. LLBH Private Wealth Management LLC increased its stake in Capricor Therapeutics by 27.7% during the 2nd quarter. LLBH Private Wealth Management LLC now owns 184,591 shares of the biotechnology company’s stock valued at $153,000 after purchasing an additional 40,000 shares in the last quarter. Virtu KCG Holdings LLC increased its stake in Capricor Therapeutics by 571.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 179,301 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 152,614 shares in the last quarter. Finally, Wells Fargo & Company MN acquired a new position in Capricor Therapeutics during the 3rd quarter valued at approximately $107,000.

ILLEGAL ACTIVITY WARNING: “Capricor Therapeutics Inc (CAPR) Shares Up 11.3%” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/capricor-therapeutics-inc-capr-shares-up-11-3/1703244.html.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.